TMCnet News
PennyStockScholar.com: SIRIUS XM Radio (NASDAQ: SIRI), Cannabis Science, Inc. (OTCBB: CBIS), Dynavax Technologies Corporation (NASDAQ: DVAX): Sign-Up for our FREE Stock Picks TODAY!(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:28122010 www.PennyStockScholar.com SIRIUS XM Radio (NASDAQ: SIRI), Cannabis Science, Inc. (OTCBB: CBIS), Dynavax Technologies Corporation (NASDAQ: DVAX) Sign-Up for our FREE Stock Picks AND OUR AWARD WINNING NEWSLETTER at www.PennyStockScholar.com ____________________________________________________________________________ Visit: www.PennyStockScholar.com for current profiles. SIRIUS XM Rocks in the New Year With Live Concerts Across Multiple Music Channels "New Year's Nation" pop-up channel serves as North America's party soundtrack for New Year's Eve NEW YORK, Dec. 23, 2010 -- SIRIUS XM Radio (Nasdaq: SIRI) announced today that it will celebrate the new year with a wide-ranging lineup of live concerts, special performances, exclusive DJ sets, a special New Year's Eve music channel and various year-end countdowns. SIRIUS XM will broadcast Eminem's sold-out "Home & Home" concert, recorded live at Comerica Park in the rap legend's hometown, Detroit, MI, exclusively on his SIRIUS XM channel, Shade 45, SIRIUS channel 45 and XM channel 66. The highly acclaimed concert features appearances by 50 Cent, Drake, B.O.B. and Dr. Dre. The concert will air on Friday, December 31 at 8:00 pm ET. Listeners will also hear a special encore broadcast of Paul McCartney's performance from the world famous Apollo Theater from December 13. The concert, which celebrated SIRIUS XM reaching 20 million subscribers, was broadcast live on six SIRIUS XM channels. The special encore broadcast will air on The Bridge, SIRIUS channel 33 and XM channel 27, on Friday, December 31 at 9:00 pm ET. SIRIUS XM listeners will hear live concert broadcasts from all over the country featuring an eclectic lineup of world-class talent, including Furthur's concert from Bill Graham Civic Auditorium in San Francisco, CA; The Disco Biscuits' concert from the Tower Theatre in Philadelphia, PA; Southside Johnny at Count Basie Theatre in Red Bank, NJ; Patti Smith at Bowery Ballroom in New York City, NY; The Avett Brothers' at Ashville Civic Center in Asheville, NC; Phil Vassar's concert from downtown Nashville, TN; Drive By Truckers' concert from Terminal 5 in New York, NY; Pitbull's concert from House of Blues in Las Vegas, NV; and Little Feat's concert at the Keswick Theatre in Glenside, PA. SIRIUS XM listeners will also hear broadcasts of historic and special concerts by Bruce Springsteen, Willie Nelson, Frank Sinatra, David Bowie, Flaming Lips, Jack Johnson, Phoenix, Bachman & Turner, Peter Noone, Gerald Albright and Vampire Weekend. Internationally-renowned DJ Paul Oakenfold will spin live from Rain in Las Vegas and Swedish House Mafia's Steve Angello will DJ live from Roseland in New York, NY. In addition, listeners will hear DJ sets by Paul van Dyk, Armin van Buuren, Swedish House Mafia's Axwell, as well as a special presentation of Tim Berg presents "Avicii LEV7LS" on New Year's Eve. The DJ sets will air on Electric Area, SIRIUS channel 38 and XM channel 80. Real Jazz, SIRIUS channel 72 and XM channel 70, presents NPR's 30th "Toast of the Nation" featuring live jazz, coast to coast, with performances from Dianne Reeves, Lionel Loueke Trio, Jon Faddis Jazz Orchestra with Nnenna Freelon, Jimmy Heath, Cyrus Chestnut, Nicholas Payton and Benny Green. Metropolitan Opera Radio, SIRIUS channel 78 and XM channel 79, will present a live broadcast of the new production premiere Verdi's: La Traviata. SIRIUS XM's New Year's Nation channel, SIRIUS channel 3 and XM channel 23, is custom-created to serve as the ultimate soundtrack to New Year's Eve parties around the country and will feature the biggest, upbeat party hits from genres across SIRIUS XM's music platform. The channel will launch on Friday, December 31 at 12:00 pm ET and will air through Saturday, January 1 at Midnight ET. SIRIUS XM's various decades and wide-ranging genre channels will each offer special New Year's Eve programming, including countdowns, the best of in-studio performances, interviews and more. For more information, please visit www.sirius.com or www.xmradio.com. About SIRIUS XM Radio SIRIUS XM is America's satellite radio company, broadcasting more than 135 channels of commercial-free music, and premier sports, news, talk, entertainment, traffic, weather, and data services to more than 20 million subscribers in cars, trucks, boats and aircraft, and through a wide range of mobile devices. SIRIUS XM offers an array of content from some of the biggest names in entertainment, as well as from professional sports leagues, major colleges, and national news and talk providers. SIRIUS XM programming is also available at sirius.com and xmradio.com, and on Apple iPhone and iPod touch, BlackBerry and Android-powered mobile devices using the SIRIUS XM Premium Online App. SIRIUS XM has arrangements with every major automaker and its radio products are available at retail locations nationwide, as well as shop.sirius.com and shop.xmradio.com. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, the combined company's plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intend," "plan," "projection," "outlook" or words of similar meaning. Such forward-looking statements are based upon the current beliefs and expectations of SIRIUS XM's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the control of SIRIUS and XM. Actual results may differ materially from the results anticipated in these forward-looking statements. The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statement: our dependence upon automakers and other third parties, the substantial indebtedness of SIRIUS and XM; the useful life of our satellites; and our competitive position versus other forms of audio and video entertainment. Additional factors that could cause SIRIUS' and XM's results to differ materially from those described in the forward-looking statements can be found in SIRIUS' Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the period ending September 30, 2010 and XM's Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the period ending September 30, 2010, which are filed with the Securities and Exchange Commission (the "SEC") and available at the SEC's Internet site (http://www.sec.gov). The information set forth herein speaks only as of the date hereof, and SIRIUS and XM disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this communication. Follow SIRIUS XM Radio on Twitter or like the SIRIUS XM Radio page on Facebook. ____________________________________________________________________________ Visit: www.PennyStockScholar.com for current profiles. Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan COLORADO SPRINGS, Colo., Dec. 23, 2010-- Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, announced today that it has formed a Military Advisory Board, that will be comprised of distinguished military leaders, military Health Care Providers, Researchers and Educators. The Cannabis Science Military Advisory Board will be comprised of individuals with career experience with the Department of Defense (DoD), Department of Veterans Affairs, The Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury and The Department of Health and Human Services. Under the partnership with Leading Points Corporation and its President, Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan, the Cannabis Science Military Advisory Board will help identify and develop actionable policies to help ease the burden on veterans serving with debilitating injuries and illnesses. The board will provide an institutionalized conduit for the evolving concerns of military veterans to be brought to the attention of senior policymakers and the public. LTC (Ret.) Kevin Sullivan stated, "The military advisory board is committed to ensuring servicemembers, veterans and families who are dealing with psychological health conditions such as Post Traumatic Stress Disorder and traumatic brain injury (TBI) challenges have access to all options of quality treatments available. We will represent the company in respect to a number of federal initiatives and insure that the company is positioned to support the development of any federal programs through clinical studies, education and treatment." Dr. Robert Melamede, PhD., Cannabis Science President and CEO, explained, "As a board, their mission will be to share their knowledge and experience by helping Cannabis Science's senior management team to understand the needs of the military market and to deliver products that meet those needs. As we continue to diversify our company, the U.S. government, and specifically the military and federal government channels, will continue to present us with opportunities for growth. We are excited about this high-level of expertise our Military Advisors will bring to the company, and we look forward to their contributions in helping us represent the brave men and women who have given so much for each of us." Lt. Col. Sullivan further stated, "In early 2011, we will be submitting a petition that asks the Colorado Department of Public Health and Environment to add PTSD (post-traumatic stress disorder) to the list of conditions for which medical cannabis can be recommended. We are beginning to see a new openness within the federal government to allow the limited and appropriate use of cannabis under a doctor's supervision. We believe our veterans should have the maximum number of treatments available to them, especially with cannabis' proven effectiveness in assisting veterans struggling with chronic and phantom limb pain, sleep disturbance, brain injuries, PTSD, anxiety and depression." About Leading Points Corporation: Leading Points Corporation, founded in 2004, specializes in marketing to the military market. They are considered the experts in matters of securing placement of their clients' products in the military exchange store distribution channel as well as special promotions to the military community. The company is headquartered in Centennial, Colorado About Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. Forward Looking Statements Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements. ____________________________________________________________________________ Visit: www.PennyStockScholar.com for current profiles. Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate BERKELEY, CA -- 12/23/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed: o All doses were generally safe and well tolerated; ando Individual immunologic and virologic responses were observed across cohorts at all dose levels. No conclusions regarding the potential clinical impact of the therapy could be reached in this small study. Dynavax's treatment approach combines both the surface and core hepatitis B virus (HBV) antigens with ISCOMATRIX® adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV. About Dynavax Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV(TM), a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com. ISCOMATRIX® is a registered trademark of CSL Behring ____________________________________________________________________________ Visit: www.PennyStockScholar.com for current profiles. About PennyStockScholar.com www.PennyStockScholar.com is the premier stop for investors who wish to experience huge profits via investing in microcap and small cap stocks with huge profit potential. Penny Stock Scholar's goal is to inform you about the hottest stocks before the rest of the market catches on. PennyStockScholar.com email report service is free to those investors who sign up on our website. Penny Stock Scholar's Alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to stocks that trade on OTC, OTCBB, NYSE, NASD, and AMEX exchanges, that have the potential of showing increased activity. To subscribe to this free service, visit the Penny Stock Scholar home page at http://www.PennyStockScholar.com and Sign up Free For "Daily Stock Alerts". Join us at http://www.PennyStockScholar.com for a complimentary subscription to the most exciting online financial newsletter. Disclaimer: Verify all claims and do your own due diligence. PennyStockScholar.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockScholar.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyStockScholar.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyStockScholar.com is owned and operated by PennyStockScholar.com. Neither PennyStockScholar.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyStockScholar.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyStockScholar.com statements and opinions and such statements and opinions cannot be considered independent. PennyStockSchol.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyStockScholar.com services are often paid for using free-trading shares. PennyStockScholar.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. Visit us for a full Disclaimer at: http://www.pennystockscholar.com/disclaimer.html To feature your publicly traded company in our alerts, email us at: [email protected] Investors can receive their FREE Newsletter subscription by clicking here: http://www.PennyStockScholar.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). (c) 2010 M2 COMMUNICATIONS |